A Study To Evaluate The Safety And Tolerability Of SB-656933-AAA Following Repeated Doses In Healthy Adult Subjects
Pulmonary Disease, Chronic Obstructive
About this trial
This is an interventional treatment trial for Pulmonary Disease, Chronic Obstructive focused on measuring COPD,, CD11b,, CXCR2,, safety,, repeat dose,, tolerability., SB-656933,
Eligibility Criteria
Inclusion Criteria:
- Healthy adult female, aged 18-65 years.
- Female must not be able to have children.
- Non-smoking for the last 6 months.
Exclusion Criteria:
- Any serious medical condition.
- Hepatitis B or C and/or HIV positive.
- Currently on HRT, or other medication except paracetamol.
- Body Mass Index >30.
Sites / Locations
- GSK Investigational Site
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Experimental
Experimental
Cohort 1
Cohort 2
Cohort 3
Subjects in Cohort 1 will receive 20 milligrams (mg) of SB-656933-AAA once daily or matching placebo once daily for 14 days.
Subjects will be administered 40 mg simvastatin on day 1 followed by a washout period of two days. From day 3, the subjects will receive 50 mg of SB-656933-AAA once daily or matching placebo once daily for 14 days. On day 17, subjects will be administered 40 mg simvastatin along with SB-656933-AAA to assess statin interaction.
Subjects will be administered 100 mg SB-656933-AAA/ day or matching placebo for 14 days. Dosing will initiate after cohort I and II have completed dosing.